We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 24, 2022

PPIs May Reduce the Efficacy of Ribociclib and Palbociclib in Patients With Metastatic Breast Cancer

BMC Cancer

 

Additional Info

BMC Cancer
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
BMC Cancer 2022 May 07;22(1)516, K Eser, AH Önder, E Sezer, T Çil, A İnal, B Öztürk, V Erçolak, BB Duman, H Çelik, T Köşeci, O Kesen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading